Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

Sezaki, Hitomi; Suzuki, Fumitaka; Kawamura, Yusuke; Yatsuji, Hiromi; Hosaka, Tetsuya; Akuta, Norio; Kobayashi, Masahiro; Suzuki, Yoshiyuki; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Miyakawa, Yuzo; Kumada, Hiromitsu

doi:10.1007/s10620-008-0500-y

Cited by 84 publications

(69 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In assessment of the relationship of certain factors to relapse and SVR in patients with thrombocytopenia, we found that male gender didn't significantly differ from female gender and this was in agreement with Sezaki et al [16] who reported that the difference in response to treatment in chronic HCV according to sex is controversial.…”

Section: Discussionsupporting

confidence: 90%

Outcome of Sofosbuvir containing Treatment Regimens in Egyptian Chronic Hepatitis C Patients with Thrombocytopenia

2017

IJSR

View full text Add to dashboard Cite

Complications during and after termination of therapy didn't significantly differ from patients with normal platelets. Significant improvement of thrombocytopenia was achieved following the course of dual therapy. Conclusion: thrombocytopenia had no impact on decreasing sustained virological response or increasing relapse with these sofosbuvir regimens. Cirrhosis and advanced Child's score are significant factors in decreasing the rate of sustained response in these patients. Further studies are needed in patients with thrombocytopenia in the era of newly developed directly acting antiviral drugs especially in cirrhotic and treatment experienced.

show abstract

Section: Discussionsupporting

confidence: 90%

Outcome of Sofosbuvir containing Treatment Regimens in Egyptian Chronic Hepatitis C Patients with Thrombocytopenia

2017

IJSR

View full text Add to dashboard Cite

show abstract

“…It is possible that the higher prevalence of viral clearance among women is associated with immunological factors 12 and genetics (in particular, the HLA DRB1*01 13 , HLA-Bw35, HLA-DRB1*8 14 and GG genotypes 15 ). To date, the only study that evaluated the influence of gender on the treatment for chronic hepatitis C genotype 1 concluded that the response to combined therapy with pegylated interferon alpha (Peg-IFN) and ribavirin (RBV) was poorer among female than among male hepatitis C-infected patients aged 50 years or older, irrespective of compliance (32% vs 63%) 16 . Previously, Hayashi et al assessed gender importance in relation to the response to conventional interferon alpha treatment (IFN) alone and concluded that women younger than 40 years of age had higher rates of sustained virological response (SVR) than did men (75% vs 33%) 17 .…”

Section: Introductionmentioning

confidence: 99%

Gender influence on treatment of chronic hepatitis C genotype 1

Narciso-Schiavon

Schiavon

Carvalho-Filho

et al. 2010

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Although various studies have been published regarding the treatment of chronic hepatitis C (CHC) with peginterferon (Peg-IFN) and ribavirin, little is known regarding the real impact of gender on the characteristics that influence the effectiveness and safety of antiviral treatment for CHC patients. The objective of this study was to evaluate the influence of gender on HCV treatment outcomes. Methods: A retrospective analytical study was conducted among selected carriers of CHC genotype 1, who were treated with Peg-IFN α-2b at a dose of 1.5 µg/kg or Peg-IFN α-2a at a dose of 180 µg/week plus a ribavirin dose of 1,000-1,250 mg/day, according to weight, between 2001 and 2007. Results: Among 181 patients undergoing treatment, the mean age was 46.4 ± 11.0 years and 46% were women. At baseline, 32% of the patients had advanced fibrosis (F3-F4 Scheuer), and 83% of the subjects had viral load > 400,000 IU/ml, without significant difference between the genders (p = 0.428 and p = 0.452, respectively). When compared with men, women had higher incidence of many adverse events such as anemia (p < 0.001) and higher need for dose reduction, for both Peg-IFN (p = 0.004) and ribavirin (p = 0.006). However, the rate of sustained virological response (SVR) did not differ between the genders: 45% (female) vs 41% (male); p=0.464. Conclusions: This study suggests that women and men react differently to combined therapy, especially in relation to the incidence of adverse events and the need for dose modification. Nevertheless, these differences do not influence the SVR rate.

show abstract

“…Some investigators found female gender as the positive predictor for SVR in RCT and in "real life condition"studies [9,24,25,56,63,64]. The others did not confirm these results [20,40,42,44,65], or even found that response to combined treatment and SVR in females 50 years old or older was poorer than in males [66]. Low estrogens level in older women could be responsible for their impaired response to antiviral treatment.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Treatment With Pegylated Interferon and Ribavirin in Patients With Chronic HCV Infection “Under Real Life“ Conditions

Speičienė

Kotovienė

Mickevičius

et al. 2014

Medicinos Teorija Ir Praktika

View full text Add to dashboard Cite

Objective. To investigate the outcomes of combined therapy of hepatitis C (HCV) patients with peginterferon and ribavirin in ”real life” practice, to compare them with data obtained in randomized clinical trials (RCT) and to evaluate possible predictors of sustained virological response (SVR). Material and methods. The retrospective study of HCV patients routinely examined and treated in the Vilnius University Hospital Santariskiu Klinikos (2003−2009 yrs) was carried out. They had undergone the treatment with combination of peginterferon alfa and ribavirin according to the Lithuanian guide. Overall 203 patients were enrolled. SVR was evaluated in 179 patients. Results. The overall rate of SVR was 43 %: in 51,3 % of naives (genotype 1 − 38,8 %, genotype 2 – 100 %, genotype 3 − 82,6 % cases) and in 28,1 % of experienced patients (genotype 1 – 17 %, and genotype 3 – 64,3 % cases). Significant relations of SVR and HCV genotype was observed: 68,9 % having genotype1 were non-responders, whereas 80 % and 75,7 % ones with genotype 2 and 3 achieved SVR (p 0.005 and p = 0.01, respectively). The inverse relation with the age (p 0.01), degree of fibrosis (p = 0.039) and previous unsuccessful treatment was confirmed by multivariate analysis. Conclusions. Data of SVR obtained „on real life“ conditions are non unambiguous: SVR of naive and experienced patients overall and those with genotype 1 were similar or slightly lower, while for patients with genotype 3 significantly higher than results presented in clinical trials. Genotype 1, previous unsuccessful antiviral treatment, older age, and advanced fibrosis were strongest negative predictors for SVR.

show abstract

Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

Abstract: Response to combined PEG-IFN and ribavirin is poorer in female than male patients with hepatitis C who are aged >or=50 years, irrespective of compliance with treatment. Low estrogen levels in older women could be responsible for their impaired response to PEG-IFN and ribavirin.

Cited by 84 publications

References 41 publications

Outcome of Sofosbuvir containing Treatment Regimens in Egyptian Chronic Hepatitis C Patients with Thrombocytopenia

Outcome of Sofosbuvir containing Treatment Regimens in Egyptian Chronic Hepatitis C Patients with Thrombocytopenia

Gender influence on treatment of chronic hepatitis C genotype 1

Efficacy of Treatment With Pegylated Interferon and Ribavirin in Patients With Chronic HCV Infection “Under Real Life“ Conditions

Contact Info

Product

Resources

About